An investigative therapy for idiopathic pulmonary fibrosis (IPF) based on inhibiting two proteins, including the cannabinoid CB1 receptor, shows potential for halting fibrosis progression, and greatly improved survival in a mouse model for human IPF. The study, “Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis,” was published…
Targeting 2 Proteins in Lungs, Including Cannabinoid Receptor, is Potential Therapy for IPF
I try to stay positive while also being realistic about the hardships that go with using supplemental oxygen 24/7. But this week I’m irritated and worn-out from the hassles I deal with daily. Here’s me being real. I’m tired of: Having to fight with my insurance and…
As the weather turns warmer, many of us will be thinking about vacations and traveling. While traveling with a lung disease does require some careful consideration, having a lung disease doesn’t mean that you have to be confined to the house. The British Lung Foundation has…
Pulmonary fibrosis is a chronic lung disease where the tissues in the lungs become hard and stiff, causing respiratory difficulties. MORE: The treatment options for pulmonary fibrosis patients. There is no cure for pulmonary fibrosis (PF), but there are treatments that can slow down the progression of the disease and help patients…
The Pulmonary Fibrosis Foundation’s 2017 Summit, where pulmonary fibrosis researchers and community members from around the world can share information and experiences, will be Nov. 9-11 in Nashville, the foundation announced. Summit organizers encourage researchers, physicians, academics, industry leaders, patients and caregivers to take part in the sessions, which will highlight developments…
This video from Big Think deals with some of the common myths surrounding depression. MORE: Did you know that pulmonary fibrosis can be difficult to diagnose and treat? Dr. Patricia Deldin from the University of Michigan Depression Center explains exactly what depression is and what it isn’t. Deldin shares that…
Antacid therapy (AAT) may lead to major digestive problems and severe lung infections in idiopathic pulmonary fibrosis (IPF) patients who take Esbriet (pirfenidone), a study reports. The research, “Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone” was published in the journal…
Boehringer Ingelheim has enrolled its first patient with progressive fibrosing interstitial lung disease (PF-ILD) in a Phase 3 clinical trial investigating the effectiveness and safety of treatment with Ofev (nintedanib). Patients with ILDs, also called diffuse parenchymal lung diseases, are often unable to breathe. The problem stems from impaired gas exchange — a consequence…
When you are diagnosed with a life-threatening illness such as pulmonary fibrosis, it is inevitable that you will feel the need to ask some big questions. Dreaded questions like “Why me?” “Why did this have to happen?” “Am I going to die?” and “How long do I…
Esbriet (pirfenidone), is an anti-fibrotic drug used in the treatment of patients with mild to moderate idiopathic pulmonary fibrosis (IPF). It’s made by the pharmaceutical company, Genentech. Find out more about Esbriet for treating idiopathic pulmonary fibrosis. A study by researchers at the University of Wisconsin found that…
